An azirine solid-state photodegradant of the CCR2/CCR5 dual antagonist BMS-813160

被引：1
|
作者：
Ayers, Sloan [1 ]
La Cruz, Thomas [1 ]
Park, Hyunsoo [2 ]
Ramirez, Antonio [1 ]
Hritzko, Benjamin [1 ]
Sarjeant, Amy [2 ]
Lin, Ziqing [1 ]
Zaretsky, Serge [1 ]
Huang, Yande [1 ]
Zang, Jia [1 ]
Yuill, Elizabeth M. [1 ]
Fenster, Michael D. B. [1 ]
机构：
[1] Bristol Myers Squibb Co, Chem Proc Dev, New Brunswick, NJ 08903 USA
[2] Bristol Myers Squibb Co, Drug Prod Dev, New Brunswick, NJ 08903 USA
来源：
TETRAHEDRON LETTERS | 2022年 / 110卷
关键词：
Azirine; Photodegradation; NMR Spectroscopy; BMS-813160; DEGRADATION; IMPURITIES; CAPTURE;
D O I：
10.1016/j.tetlet.2022.154164
中图分类号：
O62 [有机化学];
学科分类号：
070303 ; 081704 ;
摘要：
The synthesis of the CCR2/5 dual chemokine antagonist BMS-813160 (1) presented a number of interesting impurity and degradant structure elucidation challenges. This publication will focus on the structure elucidation of the solid-state photodegradant of 1 which produced an unexpected stable azirine species. The structure was elucidated by mass spectrometry and NMR, with confirmation by single-crystal X-ray crystallography. (C) 2022 Elsevier Ltd. All rights reserved.
引用
收藏
页数：4
相关论文
共 50 条
  • [1] A dual CCR2/CCR5 chemokine antagonist, BMS-813160?
    Norman, Peter
    EXPERT OPINION ON THERAPEUTIC PATENTS, 2011, 21 (12) : 1919 - 1924
  • [2] BMS-813160: A Potent CCR2 and CCR5 Dual Antagonist Selected as a Clinical Candidate
    Cherney, Robert J.
    Anjanappa, Prakash
    Selvakumar, Kumaravel
    Batt, Douglas G.
    Brown, Gregory D.
    Rose, Anne, V
    Vuppugalla, Ragini
    Chen, Jing
    Pang, Jian
    Xu, Songmei
    Yarde, Melissa
    Tebben, Andrew J.
    Paidi, Venkatram Reddy
    Cvijic, Mary Ellen
    Mathur, Arvind
    Barrish, Joel C.
    Mandlekar, Sandhya
    Zhao, Qihong
    Carter, Percy H.
    ACS MEDICINAL CHEMISTRY LETTERS, 2021, 12 (11): : 1753 - 1758
  • [3] Nivolumab and a CCR2/CCR5 dual antagonist (BMS-813160) with or without GVAX for locally advanced pancreatic ductal adenocarcinomas: Results of phase I study.
    Christenson, Eric
    Lim, Su Jin
    Wang, Hao
    Ferguson, Anna
    Parkinson, Rose
    Cetasaan, Yvette
    Rodriguez, Christina
    Burkhart, Richard
    De Jesus-Acosta, Ana
    He, Jin
    Klein, Rachel B.
    Lafaro, Kelly
    Laheru, Dan
    Le, Dung T.
    Shubert, Christopher
    Zaidi, Neeha
    Jaffee, Elizabeth M.
    Burns, William
    Narang, Amol
    Zheng, Lei
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 : 730 - 730
  • [4] Discovery of a Potent and Orally Bioavailable CCR2 and CCR5 Dual Antagonist
    Pasternak, Alexander
    Goble, Stephen D.
    Struthers, Mary
    Vicario, Pasquale P.
    Ayala, Julia M.
    Di Salvo, Jerry
    Kilburn, Ruth
    Wisniewski, Thomas
    DeMartino, Julie A.
    Mills, Sander G.
    Yang, Lihu
    ACS MEDICINAL CHEMISTRY LETTERS, 2010, 1 (01): : 14 - 18
  • [5] Eotaxin is a natural antagonist for CCR2 and an agonist for CCR5
    Ogilvie, P
    Bardi, G
    Clark-Lewis, I
    Baggiolini, M
    Uguccioni, M
    BLOOD, 2001, 97 (07) : 1920 - 1924
  • [6] Eotaxin: A CCR2 antagonist and a CCR5 agonist on human monocytes
    Ogilvie, P
    Bardi, G
    Loetscher, P
    Baggiolini, M
    Uguccioni, M
    JOURNAL OF INVESTIGATIVE DERMATOLOGY, 2000, 115 (03) : 532 - 532
  • [7] Dual Targeting Of Ccr2 And Ccr5 For Treating Pulmonary Hypertension
    Parpaleix, A.
    Amsellem, V.
    Abid, S.
    Houssaini, A.
    Breau, M.
    Marcos, E.
    Sawaki, D.
    Bizard, E.
    Hubeau, C.
    Evans, S. E.
    Delcroix, M.
    Quarck, R.
    Adnot, S.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2016, 193
  • [8] Discovery of a dual CCR2/CCR5 antagonist with a superior cardiovascular profile for the treatment of autoimmune diseases
    Hughes, Robert O.
    Rogier, D. Joseph
    Devraj, Rajesh
    Xue, Chu-Biao
    Cao, Ganfeng
    Turner, Steven R.
    Morton, Philip A.
    Keys, Kelly
    Covington, Maryanne
    Bond, Brian R.
    Yu, Ying
    Meade, Holly
    Hood, William F.
    Roeberds, Steve
    Newton, Robert
    Metcalf, Brian
    ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2011, 242
  • [9] Molecular determinants of antagonist interactions with chemokine receptors CCR2 and CCR5
    Dawson, John R. D.
    Kufareva, Irina
    BIOPHYSICAL JOURNAL, 2023, 122 (03) : 185A - 185A
  • [10] Dual CCR5/CCR2 targeting: opportunities for the cure of complex disorders
    Laura Fantuzzi
    Maria Tagliamonte
    Maria Cristina Gauzzi
    Lucia Lopalco
    Cellular and Molecular Life Sciences, 2019, 76 : 4869 - 4886
12345